Medicare Details Plan to Cover Alzheimer’s Treatments – NBC Chicago

  • Medicare Part B will cover treatments for Alzheimer’s disease that have received US Food and Drug Administration approval, according to the federal agency that administers the program for seniors.
  • Anyone who has Medicare Part B and meets “eligibility criteria” will be covered for the new antibody treatments once they are approved by the FDA.
  • The policy would provide broad access to treatments such as Lakenby’s to slow cognitive decline, although advocacy groups worry that the registries could be a barrier to treatment.

Medicare Part B According to the federal agency administering the program for seniors, it will cover treatments for Alzheimer’s disease that receive US Food and Drug Administration approval.

Anyone who has Medicare Part B and “eligibility criteria“will be covered for new antibody treatment As if Lakenby Once the FDA approved them, said Chiquita Brooks-Lasuradmin of Center for Medicare and Medicaid Serviceson Thursday.

Part B is an optional part of the Medicare program for seniors that typically covers the cost of drugs that patients cannot administer themselves, such as infusions.

The new policy will provide wider access to treatments, such as Lekembi, that slow cognitive decline.

But patients must participate in so-called registries that collect real-world data on how well the drugs work.

Brooks-Lasur said the expanded coverage would go into effect the day the FDA approved the Alzheimer’s antibody treatment. The FDA is expected to make a decision about Lakenbi on July 6.

The drug regulator’s committee of independent advisors is scheduled to meet on June 9 to discuss the data supporting Christian and Biogen’s application to the FDA to fully approve Lekembi.

The expanded coverage policy will apply to any other Alzheimer’s antibody treatment that receives full approval from the FDA. Eli Lilly plans to submit such an application for its antibody donanumab.

The FDA granted Lakenby accelerated approval in January, but Medicare severely restricts coverage for Alzheimer’s antibody treatments that have been cleared under that accelerated route.

As a result, seniors currently cannot access Lekenbi unless they are personally able to afford the drug’s $26,500 annual cost.

The Alzheimer’s Association, which lobbies for patients with the disease, has asked Medicare to lift its ban on Lekambi and fully cover the drug.

“We believe the registry as a condition of coverage is an unnecessary barrier,” said Robert Egg, the association’s chief public policy officer.

Brooks-Lasur told Congress in an April filing that the registry “does not in any way limit people’s access to the drug.” She said the goal is to have the system in place by the time the FDA makes its decision on Lekenbi on July 6.

Brooks-Lasur said Thursday that the CMS will facilitate a nationwide portal into which physicians can enter required data.

He said his agency is also in talks with several organizations that plan to set up their own registries.

a study in a pioneer medical Journal Lakenby recently estimated Medicare could cost up to $5 billion a year.

Show More
Back to top button

disable ad blocker

please disable ad blocker